Anatara Lifesciences Ltd (ANR.AX)

0.0410 -0.0020 (-4.65%) 收市：02:06PM AEST

Anatara Lifesciences Ltd

81 Flinders Street
Level 8
Adelaide, SA 5000
Australia
61 4 3802 7172
https://anataralifesciences.com

版塊: Healthcare
行業: Biotechnology
全職員工: 

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. David Lionel Brookes F.A.C.I.D., FACRRM, FAICD, MBBS	Executive Chairman	168.21k	無	1960
Mr. John Michailidis B.Sc., EMBA, M.A.I.C.D.	COO & Executive Director	118.79k	無	無
Mr. Simon Erskine	Chief Development Officer	235.21k	無	無
Jane Lowe	Managing Director of IR Department	無	無	無
Dr. Stephen Denaro AGIA, BCom, CA, GradDipApp CG, MAICD	Company Secretary	無	無	無
Ms. Hayley van der Meer B Biomed Sc, Grad Dip Marketing Management	Commercial Manager	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 AUD。

描述

Anatara Lifesciences Ltd engages in the research, development, and commercialization of evidence-based solutions for gastrointestinal diseases in animals and humans in Australia. It offers Gastrointestinal ReProgramming, a proprietary formulation that combines bromelain with other evidence-based ingredients to address the primary underlying factors associated with human gastrointestinal conditions, such as irritable bowel syndrome and inflammatory bowel disease. The company also provides Detach for the treatment of diarrhea disease in piglets; BONIFF, a revised formulation to dry feed for piglets after weaning; and ANR-pf, a proprietary formulation for poultry in water. Anatara Lifesciences Ltd was incorporated in 2010 and is based in Adelaide, Australia.

公司管治

截至 無 止，Anatara Lifesciences Ltd 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。